Haleon PLC Sponsored ADR $HLN Shares Acquired by Natural Investments LLC

Natural Investments LLC boosted its stake in Haleon PLC Sponsored ADR (NYSE:HLN) by 77.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 172,439 shares of the company’s stock after acquiring an additional 75,466 shares during the quarter. Natural Investments LLC’s holdings in Haleon were worth $1,743,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in HLN. Bank of America Corp DE grew its stake in Haleon by 116.7% in the 2nd quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock valued at $128,423,000 after acquiring an additional 6,669,923 shares during the period. Optiver Holding B.V. acquired a new stake in Haleon in the 3rd quarter valued at $45,593,000. JPMorgan Chase & Co. grew its stake in Haleon by 36.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,984,672 shares of the company’s stock valued at $107,503,000 after acquiring an additional 3,207,986 shares during the period. ABC Arbitrage SA grew its stake in Haleon by 159.4% in the 3rd quarter. ABC Arbitrage SA now owns 2,727,350 shares of the company’s stock valued at $24,464,000 after acquiring an additional 1,675,889 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in Haleon by 3,548.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,684,968 shares of the company’s stock valued at $17,473,000 after acquiring an additional 1,638,784 shares during the period. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Stock Down 0.2%

Shares of HLN opened at $9.83 on Tuesday. The firm has a market cap of $43.81 billion, a P/E ratio of 25.19 and a beta of 0.26. Haleon PLC Sponsored ADR has a 12-month low of $8.71 and a 12-month high of $11.42. The company’s 50-day moving average price is $10.44 and its 200 day moving average price is $9.93. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 0.47.

Haleon (NYSE:HLN) last issued its quarterly earnings data on Saturday, February 14th. The company reported $6.32 earnings per share (EPS) for the quarter. The company had revenue of $3.65 billion during the quarter. On average, sell-side analysts forecast that Haleon PLC Sponsored ADR will post 0.43 earnings per share for the current year.

Haleon Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Thursday, May 14th. Stockholders of record on Friday, April 10th will be paid a $0.1307 dividend. The ex-dividend date of this dividend is Friday, April 10th. This represents a dividend yield of 266.0%. Haleon’s dividend payout ratio (DPR) is presently 64.10%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft cut shares of Haleon from a “hold” rating to a “sell” rating in a research note on Monday, January 12th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haleon in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Argus raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, March 17th. Finally, HSBC raised shares of Haleon from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.33.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.